Yatsen
Yatsen's revenue rose 26.7% to CN¥4.3 billion in fiscal 2025. Its operating margin was −4.3%, up from −24.3% a year earlier. Free cash flow was −CN¥137 million. It paid out CN¥111 million in dividends and buybacks. The diluted share count fell 8.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
Yatsen lost money in fiscal 2025: a net loss of CN¥81 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 3,138 | 2,586 | 2,055 | 1,356 | 1,011 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.2x | 6.0x | 4.8x | 3.7x | 3.6x |
| Quick ratio | 4.4x | 5.2x | 4.2x | 3.1x | 2.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −12.3% | −9.4% | 23.5% |
| Altman Z'' | 2.34 | −1.50 | −0.74 |
| Accruals ratio | −11.8% | −10.3% | 0.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Yatsen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Yatsen | FY25 | 26.7% | −4.3% | −3.2% | — | — | — | |
| Herbalife | FY25 | 0.9% | 9.6% | 5.0% | 36.6% | 2.7x | 6 | Compare |
| Coty | FY26 | −1.5% | −1.4% | 6.0% | −0.9% | 7.3x | 3 | Compare |
| Haleon | FY25 | −1.8% | 21.9% | 21.0% | 7.9% | 2.6x | 7 | Compare |
| e.l.f. Beauty | FY26 | 24.6% | 4.5% | 11.6% | 3.8% | 3.6x | 4 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 635 | 3,031 | 5,233 | 5,840 | 3,706 | 3,415 | 3,393 | 4,298 |
| Revenue growth | — | 377.1% | 72.7% | 11.6% | −36.5% | −7.9% | −0.6% | 26.7% |
| Gross profit | 403 | 1,928 | 3,364 | 3,899 | 2,519 | 2,513 | 2,617 | 3,361 |
| Research and development | 3 | 23 | 66 | 142 | 127 | 112 | 109 | 137 |
| Operating income | −33 | 144 | −2,683 | −1,624 | −929 | −913 | −825 | −186 |
| Net income | −40 | 75 | −2,688 | −1,541 | −815 | −748 | −708 | −81 |
| Diluted EPS (CNY) | −0.17 | −0.10 | −4.78 | −0.61 | −0.34 | −0.34 | −0.35 | −0.04 |
| Diluted shares (millions) | 271 | 450 | 834 | 2,527 | 2,373 | 2,196 | 2,025 | 1,863 |
| Cash flow | ||||||||
| Cash from operations | −96 | −6 | −983 | −1,020 | 136 | −107 | −244 | −95 |
| Capital expenditure | 4 | 106 | 226 | 141 | 51 | 44 | 53 | 42 |
| Free cash flow | −100 | −113 | −1,209 | −1,162 | 85 | −151 | −296 | −137 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 47 | 491 | 15 | 655 | 213 | 406 | 111 |
| Acquisitions | 0 | 29 | 3 | 990 | 2 | 0 | 0 | 0 |
| Stock-based compensation | 14 | 75 | 1,901 | 530 | 341 | 78 | 91 | 59 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | — | 687 | 5,727 | 3,138 | 2,586 | 2,055 | 1,356 | 1,011 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 2,010 | 8,308 | 7,272 | 5,863 | 5,006 | 3,971 | 3,847 |
| Total liabilities | — | 936 | 1,444 | 1,264 | 800 | 821 | 868 | 846 |
| Shareholders' equity | −58 | −56 | 6,848 | 5,659 | 4,719 | 4,135 | 3,055 | 3,011 |
| Margins and ratios | ||||||||
| Gross margin | 63.5% | 63.6% | 64.3% | 66.8% | 68.0% | 73.6% | 77.1% | 78.2% |
| Operating margin | −5.2% | 4.7% | −51.3% | −27.8% | −25.1% | −26.8% | −24.3% | −4.3% |
| Net margin | −6.3% | 2.5% | −51.4% | −26.4% | −22.0% | −21.9% | −20.9% | −1.9% |
| Free cash flow margin | −15.8% | −3.7% | −23.1% | −19.9% | 2.3% | −4.4% | −8.7% | −3.2% |
| Rule of 40 (growth + FCF margin) | — | 373.4% | 49.5% | −8.3% | −34.2% | −12.3% | −9.4% | 23.5% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −79.1% | −24.6% | −15.7% | −16.9% | −19.7% | −2.7% |
| Return on assets | — | — | −52.1% | −19.8% | −12.4% | −13.8% | −15.8% | −2.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |